Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis. 18F-PSMA1007 PET/CT in the context of biochemical ...
The Punch on MSN
Emergence of HIFU treatment for prostate cancer, tumours, a game-changer – Specialists
High-Intensity Focused Ultrasound treatment, popularly known as HIFU, is fast becoming a game-changer in the management of tumours, prostate cancer and enlargement, as well as other conditions ...
If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback